Literature DB >> 22135046

The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.

Daniel W Fitzgerald1, Karl Bezak, Oksana Ocheretina, Cynthia Riviere, Thomas C Wright, Ginger L Milne, Xi Kathy Zhou, Baoheng Du, Kotha Subbaramaiah, Erin Byrt, Matthew L Goodwin, Arash Rafii, Andrew J Dannenberg.   

Abstract

Human immunodeficiency virus (HIV-1) infection causes chronic inflammation. COX-2-derived prostaglandin E(2) (PGE(2)) has been linked to both inflammation and carcinogenesis. We hypothesized that HIV-1 could induce COX-2 in cervical tissue and increase systemic PGE(2) levels and that these alterations could play a role in AIDS-related cervical cancer. Levels of cervical COX-2 mRNA and urinary PGE-M, a biomarker of systemic PGE(2) levels, were determined in 17 HIV-negative women with a negative cervical human papilloma virus (HPV) test, 18 HIV-infected women with a negative HPV test, and 13 HIV-infected women with cervical HPV and high-grade squamous intraepithelial lesions on cytology. Cervical COX-2 levels were significantly associated with HIV and HPV status (P = 0.006 and 0.002, respectively). Median levels of urinary PGE-M were increased in HIV-infected compared with uninfected women (11.2 vs. 6.8 ng/mg creatinine, P = 0.02). Among HIV-infected women, urinary PGE-M levels were positively correlated with plasma HIV-1 RNA levels (P = 0.003). Finally, levels of cervical COX-2 correlated with urinary PGE-M levels (P = 0.005). This study shows that HIV-1 infection is associated with increased cervical COX-2 and elevated systemic PGE(2) levels. Drugs that inhibit the synthesis of PGE(2) may prove useful in reducing the risk of cervical cancer or systemic inflammation in HIV-infected women. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22135046      PMCID: PMC3252428          DOI: 10.1158/1940-6207.CAPR-11-0496

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  48 in total

1.  Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.

Authors:  H Sheng; J Shao; M K Washington; R N DuBois
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

2.  Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Authors:  M Frisch; R J Biggar; J J Goedert
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  Cyclooxygenase-2 is overexpressed in human cervical cancer.

Authors:  S Kulkarni; J S Rader; F Zhang; H Liapis; A T Koki; J L Masferrer; K Subbaramaiah; A J Dannenberg
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

4.  Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

Authors:  G Ferrandina; L Lauriola; M G Distefano; G F Zannoni; M Gessi; F Legge; N Maggiano; S Mancuso; A Capelli; G Scambia; F O Ranelletti
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion.

Authors:  H S Ryu; K H Chang; H W Yang; M S Kim; H C Kwon; K S Oh
Journal:  Gynecol Oncol       Date:  2000-03       Impact factor: 5.482

6.  Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions.

Authors:  C F Pereira; L A Boven; J Middel; J Verhoef; H S Nottet
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

7.  Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T cells in HIV type 1 myocarditis.

Authors:  Q N Liu; S Reddy; J W Sayre; V Pop; M C Graves; M Fiala
Journal:  AIDS Res Hum Retroviruses       Date:  2001-10-10       Impact factor: 2.205

8.  Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control.

Authors:  D K Gaffney; J Holden; K Zempolich; K J Murphy; A P Dicker; M Dodson
Journal:  Am J Clin Oncol       Date:  2001-10       Impact factor: 2.339

9.  Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2.

Authors:  Michel Steenport; K M Faisal Khan; Baoheng Du; Sarah E Barnhard; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.

Authors:  K J Sales; A A Katz; M Davis; S Hinz; R P Soeters; M D Hofmeyr; R P Millar; H N Jabbour
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

View more
  23 in total

Review 1.  Notes from the field: "green" chemoprevention as frugal medicine.

Authors:  Jed W Fahey; Paul Talalay; Thomas W Kensler
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

2.  Synthesis of tetranor-PGE1: a urinary metabolite of prostaglandins E1 and E2.

Authors:  Jennifer R Kimbrough; Somnath Jana; Kwangho Kim; Alexander Allweil; John A Oates; Ginger L Milne; Gary A Sulikowski
Journal:  Tetrahedron Lett       Date:  2020-04-10       Impact factor: 2.415

Review 3.  The role of antioxidants and pro-oxidants in colon cancer.

Authors:  William L Stone; Koyamangalath Krishnan; Sharon E Campbell; Victoria E Palau
Journal:  World J Gastrointest Oncol       Date:  2014-03-15

4.  Fruit and vegetable intake and urinary levels of prostaglandin E₂ metabolite in postmenopausal women.

Authors:  Sangmi Kim; Joseph Rimando; Dale P Sandler
Journal:  Nutr Cancer       Date:  2015-03-26       Impact factor: 2.900

5.  Oxidative Stress in HIV Infection and Alcohol Use: Role of Redox Signals in Modulation of Lipid Rafts and ATP-Binding Cassette Transporters.

Authors:  Samikkannu Thangavel; Carmen T Mulet; Venkata S R Atluri; Marisela Agudelo; Rhonda Rosenberg; Jessy G Devieux; Madhavan P N Nair
Journal:  Antioxid Redox Signal       Date:  2018-02-01       Impact factor: 8.401

Review 6.  Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.

Authors:  Vikrant V Sahasrabuddhe; Groesbeck P Parham; Mulindi H Mwanahamuntu; Sten H Vermund
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-12

7.  Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.

Authors:  Samuel B Anyona; Prakasha Kempaiah; Gregory C Davenport; John M Vulule; James B Hittner; John M Ong'echa; Douglas J Perkins
Journal:  Biochem Biophys Res Commun       Date:  2013-06-03       Impact factor: 3.575

8.  Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa.

Authors:  R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes
Journal:  J Clin Virol       Date:  2013-10-18       Impact factor: 3.168

9.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

10.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.